Orris

Sulbactam for renal doses

Reading File
Finding Sources
Searching PubMed

sulbactam AND renal impairment

Searching the Web

sulbactam prescribing information renal impairment dosage adjustment ampicillin sulbactam

For ampicillin-sulbactam (Unasyn) IV, reduce the dosing frequency in renal impairment. Keep the same 2:1 ampicillin:sulbactam product dose.
Creatinine clearance (CrCl)Recommended dose
≥30 mL/min/1.73 m²1.5 to 3 g IV every 6 to 8 h
15 to 29 mL/min/1.73 m²1.5 to 3 g IV every 12 h
5 to 14 mL/min/1.73 m²1.5 to 3 g IV every 24 h
  • 1.5 g = ampicillin 1 g + sulbactam 0.5 g
  • 3 g = ampicillin 2 g + sulbactam 1 g
  • Choose 1.5 versus 3 g according to infection severity/site and local protocol.
  • In hemodialysis, give the scheduled dose after dialysis because both components are dialyzable. Confirm the exact timing with the local renal-antimicrobial guideline.
This applies to the ampicillin-sulbactam combination, not sulbactam-durlobactam (Xacduro), which has a different renal-dose regimen. The current FDA Unasyn label provides this table.

Sulbactam for acinetobacter coverage

Reading File
Reading File
Finding Sources
Searching PubMed

Acinetobacter baumannii AND sulbactam

Searching the Web

IDSA 2024 guidance carbapenem-resistant Acinetobacter baumannii sulbactam durlobactam high-dose ampicillin sulbactam

Reading Web Page

https://www.idsociety.org/practice-guideline/amr-guidance

Sulbactam has intrinsic activity against Acinetobacter baumannii, not merely beta-lactamase inhibition. It binds Acinetobacter PBPs, so it is the active component in ampicillin-sulbactam for susceptible isolates and in high-dose regimens for CRAB.

Invasive CRAB infection

Current preferred treatment is:
  • Sulbactam-durlobactam + imipenem-cilastatin or meropenem, if available.
If not immediately available, use a temporary combination regimen:
  • Ampicillin-sulbactam 9 g IV every 8 hours as a prolonged infusion
    • This equals 6 g ampicillin + 3 g sulbactam per dose
    • Total = 9 g/day of sulbactam
  • Plus one additional active drug, commonly cefiderocol, minocycline, or polymyxin B, tailored to susceptibility and infection site.
The IDSA AMR guidance recommends this high-dose ampicillin-sulbactam combination only as a bridge until sulbactam-durlobactam plus a carbapenem can be started for invasive CRAB.

If isolate is sulbactam-susceptible

For non-CRAB or clearly susceptible Acinetobacter, standard ampicillin-sulbactam may be adequate, for example:
  • 3 g IV every 6 hours
    • Provides sulbactam 1 g every 6 h, or 4 g/day.
For severe pneumonia, bacteremia, CNS infection, or carbapenem-resistant isolates, involve ID/stewardship and use high-dose/combination treatment rather than assuming standard-dose Unasyn is sufficient.
Renal impairment: high-dose CRAB regimens require individualized interval adjustment. Do not simply apply the usual renal-dose table without confirming with your local antimicrobial/ID pharmacist, since the aim is to preserve sulbactam exposure. Recent reviews include a pharmacokinetic systematic review (PMID 40903201) and sulbactam-durlobactam resistance review (PMID 41156673).
This is a shared conversation. Sign in to Orris to start your own chat.